Arca Biopharma (ABIO) has released an update to notify the public and investors about the submission of matters to a vote of security holders.
At the 2023 Annual Meeting held on January 30, 2024, the Company’s stockholders voted in favor of electing Dr. Michael R. Bristow and Mr. Robert E. Conway to the Board for a three-year term, ratifying KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023, and approving the compensation of the Company’s named executive officers. The voting results confirmed a majority in favor of all items on the agenda, including the election of directors and advisory approval of executive compensation.
For further insights into ABIO corporate activity, check out TipRanks’ Insiders Trading Activity page.
For a comprehensive understanding of the announcement, you can read the full document here.
